Organic Selenium Reaches the Central Nervous System and Downmodulates Local Inflammation: A Complementary Therapy for Multiple Sclerosis?

Juliana Helena dos Santos de Toledo, Thais Fernanda de Campos Fraga-Silva, Patrícia Aparecida Borim, Larissa Ragozo Cardoso de Oliveira, Evelyn da Silva Oliveira, Larissa Lucena Périco, Clélia Akiko Hiruma-Lima, Adriana Aparecida Lopes de Souza, Carlos Alberto Ferreira de Oliveira, Pedro de Magalhães Padilha, Marcos Felipe Pinatto-Botelho, Alcindo Aparecido dos Santos, Alexandria Sartori and Sofia Fernanda Gonçalves Zorzella-Pezavento

Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system (CNS). The persistent inflammation is being mainly attributed to local oxidative stress and inflammasome activation implicated in the ensuing demyelination and axonal damage. Since new control measures remain necessary, we evaluated the preventive and therapeutic potential of a beta-selenium-lactic acid derivative (LAD-βSe), which is a source of organic selenium under development, to control experimental autoimmune encephalomyelitis (EAE) that is an animal model for MS. Two EAE murine models: C57BL/6 and SJL/J immunized with myelin oligodendrocyte glycoprotein and proteolipid protein, respectively, and a model of neurodegeneration induced by LPS in male C57BL/6 mice were used. The preventive potential of LAD-βSe was initially tested in C57BL/6 mice, the chronic MS model, by three different protocols that were started 14 days before or 1 day, and 7 days after EAE induction and were extended until the acute disease phase. These three procedures were denominated preventive therapy −14 days, 1 day, and 7 days, respectively. LAD-βSe administration significantly controlled clinical EAE development without triggering overt hepatic and renal dysfunction. In addition of a tolerogenic profile in dendritic cells from the mesenteric lymph nodes, LAD-βSe also downregulated cell amount, activation status of macrophages and microglia, NLRP3 (NOD-like receptors) inflammasome activation and other pro-inflammatory parameters in the CNS. The high Se levels found in the CNS suggested that the product crossed the blood-brain barrier having a possible local effect. The hypothesis that LAD-βSe was acting...
INTRODUCTION

Multiple sclerosis (MS) is a chronic and inflammatory condition of the central nervous system (CNS) whose prevalence is clearly increasing in many countries (1). Symptomatology and patient’s disability are consequences of the presence of demyelinating lesions in the CNS and include weakness, fatigue, incontinence and paralysis (2). The immunopathogenesis of these lesions is complex and involves the interplay of distinct subsets of T lymphocytes. Autoreactive T cells specific for myelin peptides, probably activated in the peripheral lymphoid organs by molecular mimicry or bystander activation, migrate toward the CNS and target the myelin sheath-producing oligodendrocytes, triggering a local inflammatory and injurious process (3, 4). Classically, Th1 and Th17 cells, locally reactivated by myelin presented by microglia act mainly by releasing pro-inflammatory cytokines as IFN-γ, TNF-α, IL-6 and IL-17 (5). Th17 cells have also being associated to blood-brain barrier (BBB) disruption, facilitating therefore lymphocyte transmigration to the CNS (6). Local antigen presentation, that takes place in the presence of MHCII and co-stimulatory molecules, allows T cell reactivation in the CNS and is viewed as a crucial event for disease evolution (7). Different cell types as peripheral dendritic cells (DCs), infiltrating macrophages, CNS-resident microglia, and T lymphocytes (Th1, Th17, and Tregs) have been extensively investigated concerning their contribution to this neuroinflammatory process (8, 9).

This orchestrated cell interplay will, ultimately, generate inflammation and subsequent neurodegeneration. Strong evidences indicate that oxidative stress is a dominant trigger of inflammation and vice versa and that this cyclical process is implicated in both, demyelination and axonal damage processes (10). A close relationship between the oxidative stress and the activation of the inflammasome platform has been described. CNS reactive species of oxygen (ROS) are mostly produced by infiltrating macrophages and activated microglia. In addition to direct damage to the BBB and myelin sheath (11, 12), ROS are also considered the main inflammasome activators (13). The inflammasomes are innate system receptors that perceive inflammatory signals coming from infections or from host derived molecules. Several inflammasomes have been identified so far but NOD-like receptor pyrin/domain-containing-3 (NLRP3) inflammasome is currently the best characterized complex involved in the pathogenesis of chronic inflammatory and autoimmune conditions including MS (14). Briefly, pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) interaction with Toll-like receptors (TLRs) triggers NF-κB activation, promoting the transcription of NLRP3, pro-IL-1β, and pro-IL-18. Subsequent stimuli as presence of ROS, potassium efflux, calcium influx or mitochondrial damage, allows oligomerization of the inflammasome complex and subsequent release of active IL-1β and IL-18 (15). In addition of being essential mediators of innate immunity, IL-1β and IL-18 play important roles instructing Th1 and Th17-types of polarization (15).

Although there is no cure for MS yet, the current therapy, which is essentially based on the application of immunomodulatory drugs, can reduce the intensity and number of disease relapses (16, 17). Alternative and adjunct therapies have been largely investigated, including compounds derived from helminths (18), medical cannabis (19) and vitamin D (20). In the last few years our research group has been using experimental autoimmune encephalomyelitis (EAE) to investigate alternative or adjunct therapies for MS (21–23). EAE is used worldwide as a study tool to allow a deeper comprehension of MS immunopathogenesis. C57BL/6 mice develop a chronic type of disease characterized by only one peak of CNS inflammation and demyelination, whereas SJL/J mice mimics the relapsing-remitting MS (RRMS), featured by periods of stability in between relapses. Notably, around 85% of the patients develop this type of disease (24). Both murine models are largely employed to study new prophylactic and therapeutic approaches, but SJL/J mice also contributes to the development of drugs to reduce the intensity or frequency of relapses (25).

Many of the drugs currently elected for MS therapy were assayed and validated by pre-clinical investigations performed with the EAE model (25). Despite the variety of medications, some patients do not respond to available therapies and the global inhibition of the immune system can trigger collateral effects as increased susceptibility to infections (26).

In the light of MS immunopathogenesis, a product with the ability to control ROS production and/or inflammasome activation and capable of reaching the CNS seemed logical to be tested. From this perspective, selenium (Se) is a micronutrient essential for normal physiological processes that is endowed with antioxidant and anti-inflammatory properties (27). It is involved in the mitochondrial dynamics, calcium channels and free radical regulation, that are all pathways implicated in MS evolution (11, 27, 28). In addition, Se supplementation can induce a regulatory phenotype in Th cells (29), reduce the

Keywords: multiple sclerosis, experimental autoimmune encephalomyelitis, selenium, microglia, inflammasome
expression of adhesion factors as E-selectin (30) and polarize macrophages to an anti-inflammatory profile (31). Se supplementation has already been effective in the control of Parkinson and other possible autoimmune conditions (11, 32, 33). Its beneficial effects depend mainly on its incorporation into proteins that will mediate the activation, proliferation and differentiation of innate and adaptive immune components (11, 29). Se-containing amino acids, such as selenocysteine and selenium-methionine, can provide direct antioxidant benefits and can also be incorporated into the synthesis of antioxidant enzymes, as glutathione peroxidase, thioredoxin reductases and methionine sulfoxide reductases (28). Synthetic compounds containing organic Se mimic the effects of human selenized proteins, including antioxidant activity (34).

In this context, we showed that a beta-selenium-lactic acid derivative (LAD-βSe) was able to significantly control the clinical development of the two most employed murine experimental models of MS. We also found that this product reaches the CNS and downmodulates pivotal parameters locally involved in neurodegeneration.

**MATERIALS AND METHODS**

**Experimental Design**

In this study were used two different murine models to evaluate the preventive and therapeutic potential of LAD-βSe to control EAE development: C57BL/6 mice as a chronic MS model and SJL/J as a relapsing-remitting one. The preventive potential of LAD-βSe was tested in C57BL/6 mice by three different protocols that started 14 days before EAE induction and extended until the acute disease phase (day 18). In this case, the animals were allocated into five groups: Control (normal healthy mice injected with the vehicle); Control/EAE (non-treated sick group injected with the vehicle); LAD-βSe -14 days/EAE (sick group treated with LAD-βSe starting 14 days before EAE induction); LAD-βSe 1 day/EAE (sick group treated with LAD-βSe starting 1 day after EAE induction); LAD-βSe 7 days/EAE (sick group treated with LAD-βSe starting 7 days after EAE induction). Weight and clinical score were evaluated daily whereas the other analyses were done at the acute disease phase which occurred at the 18th day after disease induction. Serum samples were employed for biochemical analysis of hepatic and renal function, mesenteric lymph nodes for Foxp3+ Treg cells frequency and maturation status of dendritic cells (DCs), and CNS for oxidative stress, selenium levels, macrophage/microglial cells evaluation and inflammatory parameters. In the relapsing-remitting murine model, SJL/J mice were treated with LAD-βSe soon after the first remitting episode and the analyzes were done 42 days after EAE induction. The animals were allocated into three groups: Control (normal healthy mice injected with the vehicle); Control/EAE (non-treated sick group injected with the vehicle); LAD-βSe/EAE (sick group treated with LAD-βSe starting 20 days after EAE induction). Weight and clinical score were checked daily whereas oxidative stress and inflammatory parameters in the CNS were evaluated at the relapsing peak observed 42 days after disease induction. A model of neurodegeneration induced by LPS in male C57BL/6 mice was also employed. In these experiments, the animals were allocated into three groups: Control (normal healthy mice injected with the vehicle); LPS (non-treated group injected with two doses of LPS); LPS/LAD-βSe (group injected with two doses of LPS and treated with seven doses of LAD-βSe starting 5 days before LPS administration). One day after last LPS administration, we evaluated the oxidative stress, selenium levels, and inflammatory parameters at the CNS. All these pro-inflammatory parameters were determined only by real time RT-PCR, that is, they were not complemented by evaluation of the corresponding proteins, constituting, therefore, a limitation of this aspect of this investigation.

**Mice**

Male and female C57BL/6 mice with 8–9 weeks old were purchased from the University of São Paulo (USP, Ribeirão Preto, SP, Brazil) and female SJL/J mice with 10–12 weeks old were breed in the Animal Facility of the Department of Chemical and Biological Sciences (UNESP, Botucatu, SP, Brazil), according to the local Ethics Committee on Use of Animals (CEUA - protocol number 1016/2017). Mice were maintained in a specific pathogen-free facility and received sterilized food and water ad libitum. Animals were anesthetized with ketamine/xylazine and then perfused with 10 ml of saline solution before collecting biological samples, except in the case of blood samples that were withdrawn before perfusion. All experiments were done in accordance with the local CEUA (protocol number 1114/2018).

**Beta-Selenium-Lactic Acid Derivative**

The LAD-βSe is being developed by LabSSeTe/IQ-USP (São Paulo/SP, Brazil) and Biorigin Company (Lençóis Paulista/SP, Brazil). LAD-βSe synthesis was conducted as the patent WO 2015/15543A2 (Supplementary File).

**EAE Induction**

Female C57BL/6 mice (chronic model) and female SJL/J mice (relapsing-remitting model) were subcutaneously injected, at the lower back, with 100μg of MOG35–55 (MEGVWYRSPFSRVVHLRYNGK) or 100 μg of PLP139–151 (HCLGKWLGHPDKF) peptides (both from Proteimax, São Paulo, SP, Brazil). These peptides were previously emulsified with 25μl of Complete Freund's Adjuvant (CFA) (Sigma-Aldrich, St. Louis, MO, USA) containing 2 mg/ml of Mycobacterium tuberculosis (Difco, Detroit, MI, USA). Mice also received two intraperitoneal doses of Bordetella pertussis toxin (200 ng/Sigma-Aldrich), 0 and 48 h after immunization. Control group without EAE was not injected with CFA and pertussis toxin. Clinical score and body weight were assessed daily. Clinical scores in the chronic EAE model were defined according to the following degrees of paralysis: 0– no symptoms, 1– limp tail, 2– hind legs weakness, 3– partially paralyzed hind legs, 4– complete hind leg paralysis, and 5– complete paralysis. Relapsing-remitting disease was analyzed according to the following scores: 0– no symptoms, 0.5– weak tail tip, 1– limp tail, 1.5– limp tail + one weak hind limb, 2– limp tail + two weak hind limbs, 2.5– limp tail + paralysis of one hind
limb, 3- complete hind limb paralysis, 3.5- complete hind limb paralysis + one weak forelimb, 4- complete hind limb paralysis and beginning front limb paralysis, 4.5- complete hind limb paralysis + weak forelimbs, 5- moribund or dead.

Preventive/Therapeutic Procedures

The product tested in this investigation is a LAD-ßSe, that is being developed by LabSsTe/IQ-USP (São Paulo/SP, Brazil) and Biorigin Company (Lençóis Paulista/SP, Brazil), in a cooperative program. Mice were treated daily by oral gavage with 0.125 mg of LAD-ßSe (diluted in water for injection), containing 45 µg of Se/dose. This Se dose was based on previous data published by Vieira et al. (35). Three procedures were tested in the chronic model: a preventive therapy (LAD-ßSe -14 days) approach that included 32 doses, started 14 days before EAE induction and extended up to the EAE acute phase, and a preventive therapy 1 day (16 doses) and a preventive therapy 7 days (10 doses) approaches that started on days 1 and 7 after EAE induction, respectively. The last 2 preventive therapies were also extended up to the acute disease phase (18 days after MOG injection). SJL/J mice treatment (22 doses) was initiated on day 20 which corresponds to the MOG injection). SJL/J mice treatment (22 doses) was initiated on day 20 which corresponds to the first remitting disease episode and prolonged until day 42. Control groups received the diluent by gavage following the scheme of the different protocols.

Mesenteric Lymph Node and CNS Mononuclear Cells Isolation

Mesenteric lymph nodes were collected and macerated with cell strainers in HBSS (Hanks’ Balanced Salt solution). After centrifugation at 450 xg at 4°C for 5 min the cells were resuspended in HBSS, counted and stained as described below to be further analyzed by flow cytometry. To obtain mononuclear cells from the CNS, brain and spinal cord were collected and digested with 2.5 mg/ml of collagenase D (Roche Applied Science, Indianapolis, IN, USA) and DNase (100µg/ml, Sigma-Aldrich) at 37°C for 45 min. After maceration with cell strainers, suspensions were washed in HBSS and centrifuged at 450 xg for 7 min at 18°C. Cells were resuspended in Percoll (GE Healthcare, Uppsala, Sweden) 30% and gently placed over Percoll 70%. After centrifugation at 950 xg for 20 min at 18°C, the ring containing mononuclear cells was collected and washed in HBSS. After a last centrifugation at 450 xg for 7 min at 18°C, the mononuclear cells were resuspended in HBSS, counted and stained as described below to be further analyzed by flow cytometry.

Macrophage and Microglial Cells Evaluation

The percentages of infiltrating macrophages/activated microglia (CD45^{High}CD11b^{+}) and resting microglia (CD45^{Low}CD11b^{+}) in CNS-isolated mononuclear cells were analyzed by flow cytometry. Samples were incubated with FITC labeled anti-mouse CD45 (30-F11), PerCP-Cy5.5 labeled anti-mouse CD11b (M1/70), APC labeled anti-mouse MHC II (M5/114.15.2) for 30 min at 4°C, according to manufacturer’s instructions (eBiosciences, San Diego, CA, USA). After staining, the cells were washed, resuspended in flow cytometry buffer, and fixed in paraformaldehyde 1%. Flow cytometry was performed using a FACS Canto II (Becton Dickinson - BD, California, EUA) from Institute of Biosciences (UNESP, Botucatu, SP, Brazil) and the data were analyzed with FlowJo software (Becton Dickinson - BD, California, EUA).

Treg Foxp3+ and Dendritic Cells Evaluation

The percentage of Treg cells (CD3^{+}CD4^{+}CD25^{High}Foxp3^{+}), dendritic cells (DCs) (CD11c^{+}MHCII^{+}) and tolerogenic DCs (CD11b^{+}CD103^{+}) were evaluated by flow cytometry in cells from mesenteric lymph nodes. Samples were incubated with PerCP-Cy5.5 labeled anti-mouse CD11b (M1/70), APC-Cy7 labeled anti-mouse CD11c (N418), APC labeled anti-mouse MHCII (M5/114.15.2) and PE labeled anti-mouse CD103 (2E7) panel or with PerCP-Cy5.5 labeled anti-mouse CD3 (145-2C11), PE-Cy7 labeled anti-mouse CD4 (GK1.5) and APC labeled anti-mouse CD25 (PC61.5) panel for 30 min at 4°C. Intracellular Foxp3 transcription factor was detected using Anti-mouse/rat Foxp3 Staining PE (eBiosciences, San Diego, CA, USA) according to manufacturer’s instructions. After staining, the cells were washed, resuspended in flow cytometry buffer, and fixed in paraformaldehyde 1%. Flow cytometry was performed as described above. Gate strategy for DCs was based on Ruane and Lavelle (36).

Reverse Transcriptase PCR Assays

RNA was extracted from lumbar spinal cord and lymphoid tissue (mesenteric and inguinal lymph nodes) with TRIzol reagent (Life Technologies, Austin, TX, USA). One µg of RNA was converted to CDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, California City, CA, USA) according to the manufacturer’s instructions. Tbet (Mm00450960_m1), GATA-3 (Mm0048783_m1), ORC (Mm01261022_m1), Foxp3 (Mm00475162_m1), CX3CR1 (Mm00438354_m1), iNOS (Mm00440502_m1), Arginase-1 (Mm00475988_m1), NLRP3 (Mm00434228_m1), ASC (Mm00451187_m1), caspase-1 (Mm00438023_m1) and IL-1β (Mm00434228_m1) expression were analyzed in comparison to GAPDH (Mm99999915_g1, housekeeping gene) levels. Real time PCR reactions were performed using TaqMan assays according to manufacturer’s recommendations (Applied Biosystems). Levels of gene expression were represented as relative copy numbers by using the method of delta threshold (2^{-ΔΔCt}) according to Livak and Schmittgen (37).

Hepatic and Renal Function

Concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) and alkaline phosphatase (AF) were evaluated in serum samples using commercial biochemistry kits according to manufacturer’s recommendations (Labtest Diagnostica AS, Vista Alegre, MG, Brazil). Urea and creatinine serum levels were quantified with Bioclin commercial kits (Quibasa Quimica Básica Ltda, Belo Horizonte, MG, Brazil). Results
were measured by Cobas Mira plus Chemistry Analyzer (Roche Diagnostic Systems).

**Oxidative Stress in the Lumbar Spinal Cord**

Lumbar spinal cords from C57BL/6 were initially homogenized with RIPA extraction buffer (50 mM HEPES pH 7.9, 1 M KCl, 1 M MgCl₂, 0.1 M EDTA, 0.1 M NaF) and 1% protease inhibitor cocktail. After homogenization, the samples were centrifuged at 14,000 rpm for 45 min at 4°C and the supernatants were collected and maintained at -80°C for the determination of reduced glutathione (GSH), catalase (CAT) and superoxide dismutase (SOD).

**Determination of SOD**

The supernatants were diluted in PBS (0.1 M, pH 7.2) at a ratio of 1:20 (w/v). In 100 µl of the supernatants were added 150 µl of a solution containing hypoxanthine, xanthine oxidase and nitrotetrazolium blue chloride at a ratio of 1:1:1. The absorbance was read in Eon Microplate Spectrophotometer (BioTek Instruments, Winooski, VT, USA) at 560 nm every 10 min at 37°C. The mean of the absorbance was divided by the protein concentration and the results were expressed as U of SOD/µg protein (38).

**Determination of CAT**

The supernatants were diluted in KH₂PO₄ buffer (25 mM, pH 7.5, 1 mM EDTA, and 1% BSA) at a ratio of 1:20 (w/v). Catalase was added to two wells of the plate and used as a positive control. Twenty µl of the samples were distributed in a 96-well plate with 100 µl of buffer (KH₂PO₄, 250 mM, pH 7.0), 30 µl of methanol and 20 µl of H₂O₂ (35.3 mM). The plate was held for 20 min at room temperature. After this, 30 µl of KOH (10 mM) and 45 µl of Purpald® were added and the plate was held under gentle agitation for 20 min at room temperature and protected from light. Subsequently, 15 µl of KIO₄ (65.2 mM) were added and the plate was maintained under gentle stirring for 10 min at room temperature and protected from light. Absorbance determination was performed in Eon Microplate Spectrophotometer (BioTek Instruments) at 540 nm. The concentration average was divided by the protein concentration and the results were expressed as U of CAT/µg protein (39).

**Determination of Reduced Glutathione Levels (GSH)**

The supernatants were diluted in PBS buffer in a ratio of 1:10 (w/v). The GSH levels were determined using 100 µl of Tris/EDTA buffer and 100 µl of samples and a spectrophotometer reading was performed. Then, 20 µl of 5’-5-dithio-bis-2-nitrobenzoic acid (DTNB) was added, incubated at room temperature for 15 min, and a re-reading of absorbance. The intensity of the yellow color was read using Eon Microplate Spectrophotometer (BioTek Instruments) at 412 nm. The concentration average was divided by the protein and the results were expressed in nmol of GSH/µg protein (40).

**Determination of Malondialdehyde Levels**

Brain and spinal cord from SJL/J mice (cervical and thoracic portions) were homogenized with KCl 1.15%. After centrifugation at 9000 rpm for 10 min at 4°C, the supernatants were collected and diluted in distilled water, lauryl, acetic acid and thiobarbituric acid. Samples were incubated at 95°C for 1h and then centrifuged at 4000 rpm for 10 min at 25°C. 200 µl de each sample were distributed in 96-well plates. Samples and standard curve were measured in duplicate at 532nm in Eon Microplate Spectrophotometer (BioTek Instruments). Results were expressed in nmol of malondialdehyde level (MDA)/g of tissue (41).

**Determination of Selenium Levels in the CNS**

Se levels were determined in lyophilized samples made up of brain plus the cervical and thoracic portions of the spinal cord by a graphite furnace atomic absorption spectrometry. A Shimadzu model AA-6800 atomic absorption spectrometer was used, equipped with a background absorption corrector with a deuterium lamp and self-reverse (SR) system, and a pyrolytic graphite tube with integrated platform and automatic ASC-6100 sampler. A Shimadzu hollow cathode selenium lamp operated with a 10 mA current was also used. The wavelength applied was 196.0 nm and the spectral resolution was 0.5 nm. Argon was employed as inert gas at a constant flow of 1 l min⁻¹ throughout the heating program, except during the atomization step, when the gas flow was interrupted. The absorbance signals were measured in the peak area. Sample preparation was done by particulate matter based on (42). After the sonication step of the sample in slurries and/or standard slurries directly in the auto sampler’s containers, 20 µl of standard or sample were injected into the graphite tube (coated internally with metallic tungsten), using the auto sampler’s micropipette according to Silva et al., 2006 (43).

**LPS-Induced Murine Neuroinflammation Model**

To trigger LPS neuroinflammation, C57BL/6 male mice received two intraperitoneal doses of LPS (1 mg/kg) (Sigma-Aldrich, serotype 055:B5) as described by Chen et al., 2012 (44). Mice were daily treated by gavage during 5 days before LPS administration with 0.111 mg of LAD-βSe diluted in water for injection, containing 40 µg of Se/dose. The animals also received LAD-βSe during the 2 days of LPS challenge, totaling seven LAD-βSe doses. A control group received the same diluent by gavage. Twenty-four hours after the last LPS injection, mice were anesthetized with ketamine/xylazine and perfused with 10 ml of saline solution before collection of biological samples. Brain and medulla oblongata were used to analyze the neuroinflammatory process.

**Statistical Analysis**

Data were expressed as mean ± standard deviation or as median and interquartile (25%–75%) ranges. To test normality of data, results were analyzed by Shapiro-Wilk’s test. Comparisons between experimental groups were made by t-test or One-way ANOVA followed by Tukey’s test for parametric variables and by Mann-Whitney or Kruskal-Wallis followed by Dunn’s test for nonparametric variables. Chi-square and Fisher Exact Test were performed for EAE prevalence. For comparison of EAE clinical
scores between groups, repeated measures two-way ANOVA were performed followed by a Bonferroni post hoc test. Statistical analysis was accomplished with SigmaPlot Software Version 12.0 (Systat Software Inc., San Jose, CA, USA) and p < 0.05 was considered significant.

RESULTS

Long-Term LAD-βSe Administration Reduces Clinical Severity

In a preliminary assay we tested the potential of LAD-βSe to control disease evolution. To investigate this possibility, mice were injected with LAD-βSe during 32 consecutive days beginning 14 days before and ending 18 days after EAE induction. LAD-βSe administration significantly controlled disease severity as indicated by the evident reduction in the clinical score (Figures 1A, B). This effect was associated with a discrete alteration in the inflammasome platform characterized by normal NLRP3 and ASC mRNA levels but significantly decreased levels of caspase-1 mRNA, as shown in Figure 1C. In terms of percentage, LAD-βSe administration significantly reduced the amount of CD45+ cells (infiltrating leukocytes plus microglia) and slightly reduced CD45HighCD11b- (lymphocytes) as showed in Figures 1D, G, respectively. The percentage of CD45HighCD11b- (infiltrating macrophages plus activated microglia) was not altered and of CD45LowCD11b+ (resting microglia) was increased, as illustrated at Figures 1E, F.

![Figure 1](image-url)

**FIGURE 1** | Long-term administration of beta-selenium-lactic acid derivative (LAD-βSe) controls chronic experimental autoimmune encephalomyelitis (EAE) clinical development: effect on inflammasome, infiltrating macrophages and microglia. Daily clinical score (A) and maximum clinical score (B). NOD-like receptor pyrin/ domain-containing-3 (NLRP3), ASC, and Caspase-1 transcripts (C) in the central nervous system (CNS) were analyzed by real-time RT-PCR during EAE acute phase (day 18). The levels of mRNA expression were represented by the values of 2−ΔΔct. The values obtained in the CNS analysis of healthy mice were used as reaction calibrators. The percentage of infiltrating leukocytes plus microglia (CD45+ (D), macrophages/activated microglia (CD45HighCD11b+) (E), resting microglia (CD45LowCD11b+) (F) and lymphocytes (CD45HighCD11b-) (G) cells eluted from the CNS were analyzed by flow cytometry. Mean fluorescence intensity (MFI) of the MHCII on macrophages/activated microglia (H) and resting microglial cells (I). Results represent the median ± SEM of three–six animals per group in each experiment and are representative of two independent experiments. *p < 0.05.
respectively. These two phagocytic cell populations displayed reduced expression of MHC II (Figures 1H, I).

**LAD-βSe Administration as a Preventive Therapy 1 Day or 7 Days Controls EAE Development in C57BL/6 Mice Without Causing Side Effects**

A foul breath odor in the animals’ cages during the initial long-term protocol suggested that an excess of Se was being administered to the animals. Two preventive therapeutic procedures comprising a smaller number of doses were therefore tested and initiated 1 and 7 days after EAE induction. Both strategies significantly controlled EAE progress as indicated by reduced clinical scores (Figures 2A, B). LAD-βSe treatment did not affect the usual feed consumption (not shown) and prevented weight loss (Figure 2C).

Assays to evaluate hepatic and renal functions revealed that treatments were devoid of side effects. Despite some fluctuations, the levels of alanine (Figure 2D) and aspartate aminotransferases (Figure 2E) were comparable in the 4 experimental groups. An upward trend was detected in the levels of gamma glutamyl transferase in mice treated from the 7th day on (Figure 2F). Mice with EAE presented significantly lower levels of alkaline phosphatase than normal mice and these lower levels were kept in treated mice (Figure 2G). Urea and creatinine were quantified to investigate possible kidney toxicity. Urea levels were significantly elevated in EAE mice compared to control animals. The treatment started on day 1 normalized urea levels whereas treatment started on day 7 triggered just a trend to normalization (Figure 2H). Creatinine levels were downmodulated in EAE mice; treatment started on day 1 normalized its levels and treatment started on day 7 showed a trend to normalization (Figure 2I).

---

**FIGURE 2** | Therapeutic control of chronic experimental encephalomyelitis by administration of beta-selenium-lactic acid derivative (LAD-βSe) displays no side effects. Daily clinical score (A) and maximum clinical score (B). Serum quantification of alanine aminotransferase (ALT) (D), aspartate aminotransferase (AST) (E), gamma-glutamyl transferase (GGT) (F), alkaline phosphatase (G), urea (H) and creatinine (I) was performed by biochemical assays during EAE acute phase (day 18). Body weight changes were determined by comparing the weight observed at the acute phase and at the day of experimental autoimmune encephalomyelitis (EAE) induction (C). Results represent the mean ± SEM of four–six animals per group in each experiment and are representative of 4 independent experiments. *p < 0.05.
LAD-βSe Administration as a Preventive Therapy 1 Day or 7 Days Tolerizes DCs From Mesenteric Lymph Nodes

Quantification of mRNA for Foxp3, Tbet, GATA-3, and RORγ in the inguinal lymph nodes showed no significant differences among the experimental groups (Figure 3A). Preventive therapy 1 day or 7 days with LAD-βSe significantly decreased the mRNA for CX3CR1 but did not alter the S1PR1 expression (Figure 3B).

More pronounced changes were detected in mesenteric lymph nodes. Preventive therapy 1 day reduced the percentage of activated DCs (Figure 3C) and augmented the proportion of tolerogenic DCs (Figure 3D). The percentage of CD25\textsuperscript{High}+Foxp3\textsuperscript{+} cells was not affected by treatment (Figure 3E). Contour plots representing the activated (CD11c\textsuperscript{+}MHCII\textsuperscript{+}) and tolerogenic (CD11b\textsuperscript{-}CD103\textsuperscript{+}) DCs of one representative animal from each 4 experimental groups are presented in Figure 3F. The gateway strategy used to characterize activated (CD11c\textsuperscript{+}MHCII\textsuperscript{+}) and tolerogenic (CD11b\textsuperscript{-}CD103\textsuperscript{+}) DCs, and Foxp3\textsuperscript{+} Treg cells are depicted at Supplementary Files.

LAD-βSe Reaches the CNS and Downregulates Local Inflammation

To ascertain whether LAD-βSe formulation was reaching the CNS, Se concentration was evaluated in homogenates from the whole CNS (brain plus spinal cord). As can be observed at

![Figure 3](image-url)
Figure 4A. Se levels attained high levels in treated mice, that is, about four times higher than the levels found in normal animals. The increase in Se levels was similar in the two therapeutic protocols and, in both, there was downmodulation of inflammatory parameters. The number of cells eluted from the CNS at the end of therapy was lower in treated mice; this alteration was even more evident in the early than in the delayed therapy (Figure 4B).

The cytometric analysis done with cells eluted from the CNS at the end of therapy pointed to alterations in their proportion and activation status. LAD-βSe administration significantly reduced the percentage of infiltrating leukocytes (Figure 4C), and slightly reduced the lymphocyte population (Figure 4D). The proportion of infiltrating macrophages/activated microglia was also significantly reduced by both treatments (Figure 4E).

The proportion of resting microglia (CD45	extsuperscript{Low} CD11b	extsuperscript{+}) (Figure 4F) was higher in treated groups. In addition, the treatments significantly decreased the level of MHC expression in infiltrating macrophages/activated microglia (Figure 4G) and in resting microglia (Figure 4H). Contour plots representing the infiltrating leukocytes of one representative animal from each 4 experimental groups are presented in Figure 4I. This downmodulation also

**FIGURE 4** | Therapeutic control of chronic experimental encephalomyelitis by administration of beta-selenium-lactic acid derivative (LAD-βSe) is associated with lower infiltration of macrophages and lower expression of MHC in macrophages and microglia during experimental autoimmune encephalomyelitis (EAE) acute phase (day 18). Se concentration in the central nervous system (CNS) was determined by atomic absorption spectrometry (A). Number of cells eluted from the CNS (B), percentage of infiltrating leukocytes plus microglia (CD45	extsuperscript{+}) (C), lymphocytes (CD45	extsuperscript{High}CD11b	extsuperscript{-}) (D), macrophages/activated microglia (CD45	extsuperscript{High}CD11b	extsuperscript{+}) (E), and resting microglial cells (CD45	extsuperscript{Low}CD11b	extsuperscript{+}) (F). Mean fluorescence intensity (MFI) of MHCII in macrophages/activated microglia (G) and resting microglia (H) eluted from the CNS were analyzed by flow cytometry. Contour plots representing leukocytes in the CNS of a representative animal from each experimental group (I). Results represent the median ± SEM of three–five animals per group in each experiment and are representative of two independent experiments. *p < 0.05.
included the inflammasome platform. As shown in Figure 5A, there was a significant decrease in the mRNA expression of NLRP3, caspase-1 and ASC. iNOS and arginase-1 transcripts were downmodulated in mice treated from the seventh day, but not when the treatment started 24 h after disease induction, as showed in Figure 5B. Expression of CX3CR1 mRNA was also significantly reduced by both therapies (Figure 5B). Concerning the antioxidant enzymes superoxide dismutase and catalase no significant differences were observed (data not shown). Reduced glutathione was slightly and significantly decreased by early and late therapies, respectively (Figure 5C).

LAD-βSe Downmodulates Neuroinflammation Triggered by LPS

To investigate the possibility that LAD-βSe was acting through a direct effect on the CNS, we tested its immunomodulatory activity in a model of neuroinflammation triggered by LPS. Figure 6A illustrates the effect of LAD-βSe therapy on body weight loss in mice that were injected with LPS; the two LPS inoculation moments are also indicated by arrows. As can be observed, weight loss was not avoided by the selenized compound. The presence of high Se levels in the CNS of treated mice is illustrated in Figure 6B. Many of the local parameters indicative of inflammation were significantly downmodulated by LAD-βSe administration. This was the case of malondialdehyde (Figure 6C), NLRP3 (Figure 6D), IL-1β (Figure 6E), TNF-α (Figure 6E), iNOS (Figure 6F), arginase 1 (Figure 6F), and IL-10 (Figure 6E). Other parameters as ASC (Figure 6D), caspase-1 (Figure 6D), and IFN-γ (Figure 6E) displayed just a tendency toward downmodulation.

Therapeutic Administration of LAD-βSe Controls Relapse in SJL/J Mice

Differently from the procedure adopted for C57BL/6 mice, the treatment of SJL/J mice started at the 20th day after EAE induction, that is, at the beginning of the first remission. These mice were also daily treated, and therapy was extended until day 42 after disease induction. As showed in Figure 7A, the last paralysis episode in the treated group was 2.7 times less intense than in the control one. This significant reduction in the clinical score was already been detected after 10 days of therapy and these reduced scores were maintained throughout the entire treatment (Figure 7B). CNS analysis performed after treatment, revealed significant reduction in malondialdehyde levels (Figure 7C) and in mRNA expression for NLRP3, caspase-1 and CX3CR1 (Figure 7D).
DISCUSSION

Selenium (Se) is considered a vital microelement being necessary for a plethora of biological pathways like immune system, fertility, thyroid and cardiovascular function (33). Most of its activities are preceded by its incorporation into selenoproteins and, by virtue of its similarity with sulfur, it can replace this chemical element in methionine, cysteine, and cystine and form selenium-containing amino acids. Its effects over the immune system are complex and include participation in the activation, proliferation and differentiation of innate and specific immune cells and also regulation of excessive immune response and chronic inflammation (29). In this context, we tested the potential of an organic Se source constituted by a LAD-βSe, to control the inflammation that compromises functioning of the CNS in two murine models of MS.

Initial experiments were done seeking for a proof of concept that this product under development was able to restrict EAE development. To this end, C57BL/6 mice were continuously supplemented with LAD-βSe for 32 days, beginning 14 days before and ending 18 days after EAE induction, to achieve a condition of supra physiological Se levels. This procedure was highly effective being able to significantly decrease disease severity. CNS analysis indicated clear local effects characterized by less inflammation and less activation of microglia and infiltrating macrophages. Although the results were promising, some evidences as foul breath odor in the animal’s cages suggested toxic effects associated with this prolonged protocol. LAD-βSe was then administered from the 1st or from the 7th day on after EAE induction till the acute disease phase. Both procedures were able to control disease severity without triggering any relevant changes in renal and liver functions. Interestingly, from the point of view of possible transposition to humans, the average maximum clinical score in these two groups was even lower than the observed in animals that underwent the prophylactic-therapeutic schedule.

Se supplementation is already being considered a therapeutic alternative to control inflammatory pathologies as systemic inflammatory response syndrome, asthma, type-2 diabetes, cystic fibrosis and Hashimoto’s thyroiditis (29). Nonetheless, tests with an experimental model of MS, as is the case of EAE, have not being properly carried out. Only one publication showed that diphenyl diselenide, a synthetic organoselenium compound administered by oral route, was able to reduce EAE development (45).

As with the prophylactic-therapeutic scheme, the therapeutic ones also reduced the amount and the activation status of cells directly involved in antigen presentation and neurodegeneration as infiltrating macrophages and microglia. The pivotal role of these cells to both MS and EAE immunopathogenesis is already very well established (46). We then quantified the expression of pro-inflammatory parameters usually associated with the status of infiltrating macrophages and local microglia activation, considering that Se derivatives are able to attenuate the inflammatory responses of these cells (47, 48). The observed results reinforced the local suppression of inflammation by LAD-βSe, including decreased activation of the inflammasome system and reduced expression of mRNA for iNOS and CX3CR1. The critical contribution of the inflammasome in neurodegenerative diseases is supported by many evidences (49). Pharmacological inhibition of inflammasome components is able to control EAE development and therefore is
under consideration to treat MS patients (50, 51). The drop in iNOS levels, verified in treated mice, is supported by many reports that found similar downregulation after therapy (52, 53). The impaired expression of CX3CR1 is worth mentioning because this receptor is exquisitely involved in antagonistic functions during EAE/MS development. The hallmark of those two pathologies is the heavy leukocyte infiltration into the CNS (54), and the impaired role of this receptor, during the initial disease phase, has been attributed to its ability of recruiting leukocytes to the CNS (55). The relevance of this function is illustrated by the demonstration that pharmacological inhibitors of CX3CR1 attenuated disease severity determining reduction in paralysis score, number of relapses and CNS pathology in Dark Agouti rats (56). Otherwise, fractalkine receptor (CX3CR1) deficient mice developed a worse disease that was attributed to decreased migration of NK cells to the CNS (57). NK cells local mechanism of protection has been attributed to their toxicity against encephalitogenic T cells (58). More recently, it was described that CX3CR1 expression, mainly at the microglia, was crucial for both, myelin debris removal and ensuing remyelination (58).

The marked immunomodulation locally observed suggested that LAD-βSe was reaching and acting, at least partially, in the CNS. Effectively, high Se levels, almost 4 times more than the levels found in EAE mice, were detected in the CNS of treated mice. Inspired by the knowledge that Se can upregulate CD4(+) CD25(+) regulatory T cells in other inflammatory diseases (59, 60) and that ROR</text>
triggers by LPS. Different protocols indicate that peripheral LPS injections in mice trigger neuroinflammation (65, 66). It is believed that LPS effect is mainly due to local activation of microglial cells (67, 68). In this scenario, our results showed that LAD-βSe was able to reach the CNS in this model and, in a great extent, to reduce local inflammatory parameters. Similarly to our findings, reduction in NLRP3, iNOS, and TNF-α mRNA expression have been used to ascertain the effect of anti-inflammatory drugs (69, 70).

Even though the peripheral immunological alterations have been discrete, we do not discard the possibility that they contributed to protection by additional mechanisms. As disease was induced by subcutaneous immunization at the lower back, accumulation of effector cells was expected to occur at the inguinal lymph node; they were therefore used to estimate the amount of T cell subsets by assessing their respective signature transcription factors. No significant alterations were, however, detected at the expression of mRNA coding for Foxp3, Tbet, RORc and GATA-3. As LAD-βSe was administered by oral route, the mesenteric lymph nodes were chosen to check for the presence of Tregs and DCs. Although literature data shows that Se is indeed able to increase the number of CD4+CD25+ regulatory T cells by up-regulating the expression of Foxp3 mRNA in mice (59), there was not a significant increase in the levels ofFoxp3 mRNA in the mesenteric lymph nodes. Modulation regarding DCs was detected after the long-term LAD-βSe administration procedure and involved DCs with distinct phenotypes. The clear decrease in activated DCs (CD11b+MHCII+) associated with an increase in tolerogenic DCs (CD11b+CD103+) and the known differential outcome triggered by these two APCs populations (effector and regulatory T cells differentiation, respectively) suggest that LAD-βSe is possibly interfering with this stage of the immune response. Interestingly, we also do not rule out the possibility that tolerogenic DCs are migrating from the periphery to the CNS where they could shut down lymphocyte proliferation and activation. The phenomenon of migration of this cell type and its potential therapeutic application are under investigation (71, 72).

Among MS murine models, the SJL/J strain immunized with PLP is seen as a model that mimics the relapsing-remitting form of the disease which predominates in human beings and is characterized by a series of flares-ups followed by periods of remission (73). This model was used to assess whether the treatment could restrain disease development after the first disease episode. The results clearly showed that LAD-βSe was also able to significantly reduce the severity of flare-ups.

Our findings are consistent with the pivotal role of Se in neurological health and its relevance in the context of autoimmune diseases. In murine models, for example, the genetic inactivation of selenoprotein P or its neuronal receptor, determines low Se levels in the brain, which leads to spontaneous neurological deficits and neurodegeneration (74). According to a systematic review by Sahebari et al., 2019 (75), reduced serum Se levels were detected in patients with autoimmune diseases. Notably, an adequate dietary Se intake has contributed to the management of complications in autoimmune disorders and has improved patient survival. According to this review, Se effect may be mainly mediated by its anti-inflammatory potential and this micronutrient deserves, therefore, to be considered as a possible nutritional intervention in autoimmune diseases.

Although we consider that the above results could contribute to MS control, we are aware of the existence of limitations that need to be taken into consideration. Unfortunately, we were not able, due to the reduced grant, to perform additional experiments with a pure prophylactic or a pure therapeutic regimen. This is one of the clear limitations of this investigation because this approach could help to define the most appropriate time to administer LAD-βSe to MS patients in the future. As can be realized by the results discussed above, we were also not able to provide a robust data concerning the alterations triggered by LAD-βSe on the cellular lymphoid compartment and the cellular origin of the cytokines locally produced. This limitation deserves to be addressed in future studies. This clarification will allow to confirm if this compound is actually acting, at least partially, by modulating the plethora of cell subsets that reach or that are being expanded inside the CNS itself. Lastly, and as a consequence of the short mice supply, some healthy control groups were constituted by only 3 animals. This situation did not interfere in the comparison between EAE and EAE-treated experimental groups. However, this did not allow us to know, in some situations, whether the treatment determined or not normalization of the analyzed parameter because this could lead to false positive results when treated and normal healthy control groups were statistically compared.

Altogether our findings indicate that LAD-βSe decreases EAE severity, possibly by modulating the local immune response at the CNS. Results from both models suggest that efficacy does not depend upon a precocious and prolonged LAD-βSe administration. In addition, despite the elevated Se levels found at the CNS, it does not seem to trigger relevant side effects. Future and more detailed preclinical studies will help to predict if LAD-βSe is adequate as an add-on therapy for MS patients.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by Local Ethics Committee on Use of Animals (CEUA) from São Paulo State University (UNESP), Institute of Biosciences, Botucatu, São Paulo, Brazil.

AUTHOR CONTRIBUTIONS

JT, AS, and SZ-P conceived and designed the experiments. JT, TF-S, PB, LO, and SZ-P performed the experiments. TF-S performed the flow cytometric analysis. JT, AS, and SZ-P analyzed the data. EO contributed to neuroinflammation induced by LS. LP and CH-L were responsible for oxidative
stress determination. AALS contributed to biochemistry analysis. PP was responsible for the spectrophotometric determination of selenium. MP-B, AAS, and CO synthesized the LAD-βSe. JT, AS, and SZ-P wrote the paper. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by São Paulo Research Foundation (FAPESP), grant number 2016/23318-8, National Council for Scientific and Technological Development (CNPq), grants numbers 307269/2017-5 and 152920/2018-8, and Biorigin Company. JT thanks Coordination for the Improvement of Higher Education Personnel (CAPES) for master’s degree scholarship. MP-B thanks CNPq for PhD scholarship grant number 141779/2014-4.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.571844/full#supplementary-material

**REFERENCES**

1. Vaughn CR, Jakimovski D, Kavak KS, Ramanathan M, Benedict RHB, Zivadinov R, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. *Nat Rev Neurol* (2019) 15:329–42. doi: 10.1038/s41582-019-0183-3
2. Dendrou CA, Fugger L, Friese MA. Immunopathology of MS. *Nat Rev Immunol* (2015) 15:545–58. doi: 10.1038/nri3871
3. Hartung HP, Aktas O, Menge T, Kieseier BC. Handbook of Clinical Neurology. *Nat Commun* (2018) 9:2223. doi: 10.1016/B978-0-444-52001-2.00001-7
4. Dendrou CA, Fugger L, Friese MA. Immunology of multiple sclerosis. *Nat Rev Immunol* (2015) 15:545–58. doi: 10.1038/nri3871
5. Sospedra M, Martin R. Immunology of Multiple Sclerosis. *Semin Neurol* (2005) 36:115–27. doi: 10.1055/s-0036-1579739
6. Wojkowska DW, Szpakowski P, Ksiazek-Winiarek D, Leszczynski M, Glabinski A. Interactions between neutrophils, TH17 Cells, and chemokines during the initiation of experimental model of multiple sclerosis. *Mediators Inflamm* (2014) 2014:1–9. doi: 10.1155/2014/590409
7. Waisman A, Johann L. Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity. *J Mol Med* (2018) 96:1279–92. doi: 10.1007/s00109-018-1709-7
8. Brinkmann V, Billich A, Baumrucker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. *Nat Rev Drug Discov* (2010) 9:883–97. doi: 10.1038/nrd3248
9. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. *Nat Rev Dis Primers* (2018) 9:doi: 10.1038/s41572-018-0041-4
10. Ohk T, Tenbrock K, Kipp M. Oxidative stress in multiple sclerosis. *Eur J Immunol* (2009) 39:2036–9. doi: 10.1002/eji.200939545
11. Mimura LAN, Chiuso-Minicucci F, Fraga-Silva TFC, Zorzella-Pezavento SFG, Ishikawa LLW, et al. Association of myelin peptide with vitamin D analog. *Front Immunol* (2017) 8:1198. doi: 10.3389/fimmu.2017.01198
12. Waisman A, Johann L. Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity. *J Mol Med* (2018) 96:1279–92. doi: 10.1007/s00109-018-1709-7
13. Steimann L, Shoenfeld Y. From defining antigens to new therapies in multiple sclerosis: Honoring the contributions of Ruth Arnon and Michael Sela. *J Autoimmun* (2014) 54:1–7. doi: 10.1016/j.jaut.2014.08.001
14. Schroder K, Tschopp J. Leading Edge The Inflammation in Multiple Sclerosis: Central and Peripheral Mechanisms. *FASEB J* (2015) 29:22–31. doi: 10.1096/fj.14-266073
15. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. *Nat Rev Dis Primers* (2018) 9:doi: 10.1038/s41572-018-0041-4
16. Damal K, Stoker E, Foley J. Optimizing therapeutics in the management of patients with multiple sclerosis: A review of drug efficacy, dosing, and mechanisms of action. *Biol Targets Ther* (2013) 7:247–58. doi: 10.2147/BTT.S33007
17. Yoon JH, Shoenfeld Y. From defining antigens to new therapies in multiple sclerosis: Honoring the contributions of Ruth Arnon and Michael Sela. *J Autoimmun* (2014) 54:1–7. doi: 10.1016/j.jaut.2014.08.001
18. Novikova NS, Diatlova AS, Derevtsova KZ, Korneva EA, Viktorovna FT, Ostrinski Y, et al. Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis. *J Neuroimmunol* (2019) 337:577070. doi: 10.1016/j.neuroimmunol.2019.577070
19. Katz D, Katz I, Porat-Katz BS, Shoenfeld Y. Medical cannabis: Another piece in the mosaic of autoimmunity? *Clin Pharmacol Ther* (2017) 101:230–8. doi: 10.1002/cpt.568
20. Brinkmann V, Billich A, Baumrucker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. *Nat Rev Drug Discov* (2010) 9:883–97. doi: 10.1038/nrd3248
21. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. *Nat Rev Dis Primers* (2018) 9:doi: 10.1038/s41572-018-0041-4
22. Mimura LAN, Chiuso-Minicucci F, Fraga-Silva TFC, Zorzella-Pezavento SFG, Ishikawa LLW, et al. Association of myelin peptide with vitamin D analog. *Front Immunol* (2017) 8:1198. doi: 10.3389/fimmu.2017.01198
23. Chiuso-Minicucci F, Ishikawa LLW, Mimura LAN, De Campos Fraga-Silva TF, França TGD, Zorzella-Pezavento SFG, et al. Treatment with vitamin D/ MOG associate suppresses experimental autoimmune encephalomyelitis. *PLoS One* (2015) 10:1–14. doi: 10.1371/journal.pone.0125836
24. Hohlfeld R. Multiple sclerosis: Human model for EAE? *Eur J Immunol* (2009) 39:2036–9. doi: 10.1002/eji.200939545
25. Hohlfeld R. Multiple sclerosis: Human model for EAE? *Eur J Immunol* (2009) 39:2036–9. doi: 10.1002/eji.200939545
26. Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). *Br J Pharmacol* (2011) 164:1079–106. doi: 10.1111/j.1476-5381.2011.01302.x
27. Haghikia A, Hohlfeld R, Gold R, Fugger L. Therapies for multiple sclerosis: Translational achievements and outstanding needs. *Trends Mol Med* (2013) 19:309–19. doi: 10.1016/j.molmed.2013.03.004
28. Dantas LH, Benvenega S. Sildenafil: an element for life. *Endocrine* (2014) 48:756–75. doi: 10.1007/s12020-014-0477-6
29. Solsa M, Cifelli M, Gris MV, Meneghetti C, Vecchiato G, et al. Inhibition of TNF-α induced ICAM-1, VCAM-1 and E-selectin expression by selenium. *Atherosclerosis* (2002) 161:381–6. doi: 10.1016/S0021-9150(01)00672-4
31. Nelson SM, Lei X, Prabhu KS. Selenium Levels Affect the IL-4-Induced Expression of Alternative Activation Markers in Murine Macrophages. *J Nutr Sci* (2011) 114:1754–61. doi: 10.3945/jn.111.141176

32. Chen J, Berry MJ. Selenium and selenoproteins in the brain and brain diseases. *J Neurochem* (2003) 86:1–12. doi: 10.1111/j.1471-4142.2003.01854.x

33. Rayman MP. Selenium and human health. *Lancet* (2012) 379:1256–68. doi: 10.1016/s0140-6736(11)61452-9

34. Barbosa NV, Nogueira CW, Nogara PA, De Bem AF, Aschner M, Rocha JBT. Organo-selenium compounds as mimics of selenoproteins and thiol modifier agents. *Metallomics* (2017) 9:1703–34. doi: 10.1039/c7mt00088a

35. Vieira AT, Silveira KD, Arruda MCC, Fagundes CT, Gonçalves JL, Silva TA, et al. Treatment with Selemak®, a selenium-enriched yeast, ameliorates experimental arthritis in rats and mice. *Br J Nutr* (2012) 108:1829–38. doi: 10.1017/S0007114512000013

36. Ruane DT, Lavelle EC. The role of CD103+ dendritic cells in the intestinal mucosal immune system. *Front Immunol* (2011) 2:25. doi: 10.3389/fimmu.2011.00025

37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. *Methods* (2001) 25:402–8. doi: 10.1016/meth.2001.1262

38. Winterbourn CC, Hawkins RE, Brian M, Carrell RW. The estimation of red cell superoxide dismutase activity. *J Lab Clin Med* (1975) 85:337–41.

39. Aebi H. Oxygen radicals in biological systems: Preface. *Methods Enzymol* (1979) 95:351–9.

40. Anderson ME, Ottenius S, Holmgren A, Mannervik B, Press R. Determination of Glutathione and Glutathione Disulfide in biological samples. *Methods Enzymol* (1985) 113:548–55. doi: 10.1016/s0076-6879(85)13073-9

41. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem* (1979) 95:351–9.

42. Ruane DT, Lavelle EC. The role of CD103+ dendritic cells in the intestinal mucosal immune system. *Front Immunol* (2011) 2:25. doi: 10.3389/fimmu.2011.00025

43. Liu CY, Guo SD, Yu JZ, Li YH, Zhang H, Feng L, et al. Fasudil mediates cell death. *J Neurosci* (2011) 1:116–21. doi: 10.3177/jnnp.2007.133777

44. McKenzie BA, Mamik MK, Saito LB, Boghizian R, Monaco MC, Major EO, et al. Caspase-1 inhibition prevents glial inflammation activation and pyroptosis in models of multiple sclerosis. *Proc Natl Acad Sci U S A* (2018) 115:E6065–74. doi: 10.1073/pnas.1720441115

45. McKenzie BA, Mamik MK, Saito LB, Boghizian R, Monaco MC, Major EO, et al. Caspase-1 inhibition prevents glial inflammation activation and pyroptosis in models of multiple sclerosis. *Proc Natl Acad Sci U S A* (2018) 115:E6065–74. doi: 10.1073/pnas.1720441115

46. Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. *Cell Res* (2014) 24:24–41. doi: 10.1038/cr.2013.168

47. Lubina-Dąbrowska N, Stępień K, Sulkowski G, Dąbrowska-Bouta B, Langfort J, Chalimonski M. Effects of IFN-β1a and IFN-β1b treatment on the expression of cytokines, inducible NO (NOS type II), and myelin proteins in animal model of multiple sclerosis. *Arch Immunol Ther Exp (Warsz)* (2017) 65:325–38. doi: 10.1007/s00005-017-0458-6

48. Legroux L, Arbour N. Multiple Sclerosis and T Lymphocytes : An Entangled. *J Neuroimmune Pharmacol* (2015) 10:528–46. doi: 10.1007/s13311-015-9614-0

49. Blauth K, Owens GP, Bennett JL. The ins and outs of B cells in multiple sclerosis. *Front Immunol* (2015) 6:565. doi: 10.3389/fimmu.2015.00565

50. Ridderstad Wollberg A, Ericsson-Dahlstrand A, Jureus A, Ekerot P, Simon S, Nilsson M, et al. Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. *Proc Natl Acad Sci* (2014) 111:5809–14. doi: 10.1073/pnas.1316510111

51. McKenzie BA, Mamik MK, Saito LB, Boghizian R, Monaco MC, Major EO, et al. A Novel NF-κB-Binding Site Controls Human Granzyme B Gene Transcription. *J Immuno* (2006) 176:4173–81. doi: 10.4049/jimmunol.176.7.4173

52. Hertwig L, Hamann I, Romero-Suarez S, Millward JM, Pietrek R, Chanvillard MM, et al. Treatment with Selemax® decreases Th1, Th17, and γδT and increasing CD4(+)CD25(+) regulatory T-cell responses. *World J Gastroenterol* (2017) 23:3850–63. doi: 10.3748/wjg.v23.i21.3850

53. Murphy AC, Lalor SJ, Lynch MA, Kingston HGM. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. *Brain Behav Immun* (2010) 24:641–51. doi: 10.1016/j.bbi.2010.01.014

54. McGinley AM, Edwards SD, Vareardeau M, Mills KGH. Th17 cells, γδ T cells and their interplay in EAE and multiple sclerosis. *J Autoimmun* (2018) 87:97–108. doi: 10.1016/j.jaut.2018.01.001

55. Carvalho AN, Lim JL, Nijland PG, Witte ME, Van Horssen J. Glutathione in multiple sclerosis: More than just an antioxidant? *Mult Scler* (2014) 20:4125–31. doi: 10.1177/1352458X14533400

56. Escribano BM, Medina-Fernández FJ, Aguilar-Luque M, Agüera E, Feijoo M, García-Maceira FI, et al. Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model. *Neurotherapeutics* (2017) 14:199–211. doi: 10.1007/s13311-016-0305-4

57. Hoogland ICM, Houbolt C, van Westerloo DJ, van Gool WA, van de Beek D. Systemic inflammation and microglial activation: Systematic review of animal experiments. *J Neuroinflammation* (2015) 12:1–13. doi: 10.1186/s12974-015-0332-6

58.ynn

59. Hoogland ICM, Houbolt C, van Westerloo DJ, van Gool WA, van de Beek D. Systemic inflammation and microglial activation: Systematic review of animal experiments. *J Neuroinflammation* (2015) 12:1–13. doi: 10.1186/s12974-015-0332-6

60.ynn

61.ynn

62.ynn

63.ynn

64.ynn

65.ynn

66.ynn

67.ynn

68.ynn

69.ynn

70.ynn

71.ynn

72.ynn

73.ynn

74.ynn

75.ynn

76.ynn

77.ynn

78.ynn

79.ynn

80.ynn

81.ynn

82.ynn

83.ynn

84.ynn

85.ynn

86.ynn

87.ynn

88.ynn

89.ynn

90.ynn

91.ynn

92.ynn

93.ynn

94.ynn

95.ynn

96.ynn

97.ynn

98.ynn

99.ynn

100.ynn

101.ynn

102.ynn

103.ynn

104.ynn

105.ynn
Conflict of Interest: CO was employed by Biorigin Company.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.